Derma Sciences Inc. (NASDAQ:DSCI)’s share price traded down 4.5% during trading on Tuesday . The stock traded as low as $4.95 and last traded at $5.04, with a volume of 69,426 shares traded. The stock had previously closed at $5.28.

Several equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Derma Sciences from a “hold” rating to a “buy” rating and set a $5.75 target price on the stock in a report on Wednesday, August 3rd. TheStreet raised shares of Derma Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Derma Sciences currently has a consensus rating of “Buy” and an average target price of $7.35.

The stock’s 50 day moving average price is $4.65 and its 200-day moving average price is $3.83. The firm’s market cap is $142.66 million.

Derma Sciences (NASDAQ:DSCI) last posted its quarterly earnings results on Tuesday, August 9th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.16. The business had revenue of $22.20 million for the quarter, compared to analysts’ expectations of $22.40 million. On average, analysts forecast that Derma Sciences Inc. will post ($0.04) EPS for the current year.

A hedge fund recently raised its stake in Derma Sciences stock. Royce & Associates LLC boosted its position in Derma Sciences Inc. (NASDAQ:DSCI) by 7.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 237,507 shares of the company’s stock after buying an additional 16,000 shares during the period. Royce & Associates LLC owned 0.92% of Derma Sciences worth $1,085,000 as of its most recent filing with the SEC.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.